Impact of FDA’s Actions on Novo Nordisk<\/p>\n
By Jacob Gronholt-Pedersen<\/p>\n
Stock Market Reaction<\/p>\n
COPENHAGEN, Feb 6 (Reuters) – Shares in Danish drugmaker Novo Nordisk gained 4.7% in early trading on Friday, recovering some of the previous two sessions’ steep losses, after the U.S. Food and Drug Administration (FDA) pledged to address mass-marketing of unapproved drugs.<\/p>\n
Price Pressure on Weight-Loss Medications<\/p>\n
The stock plunged nearly 8% on Thursday after telehealth company Hims and Hers Health launched a significantly cheaper $49 compounded version of Novo Nordisk’s FDA-approved Wegovy weight-loss pill.<\/p>\n
FDA’s Stance on Non-Approved Drugs<\/p>\n
“FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products,” FDA Commissioner Marty Makary said on X without naming any companies.<\/p>\n
“The FDA cannot verify the quality, safety or effectiveness of non-approved drugs,” he said.<\/p>\n
Novo warned on Wednesday of unprecedented price pressure on its weight-loss medicines and dropped its full-year forecast, triggering a 17% slump in its share price.<\/p>\n
Novo’s shares are near their lowest since Wegovy was introduced in June 2021.\u00a0<\/p>\n
By 0848 GMT the shares were up 4.9% at 294.50 Danish crowns ($46.50).<\/p>\n
($1 = 6.3327 Danish crowns)<\/p>\n
(Reporting by Jacob Gronholt-PedersenEditing by David Goodman)<\/p>\n","protected":false},"excerpt":{"rendered":"Impact of FDA’s Actions on Novo Nordisk By Jacob Gronholt-Pedersen Stock Market Reaction COPENHAGEN, Feb 6 (Reuters) –…\n","protected":false},"author":2,"featured_media":686,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[786,779,784,781,272,783,782,785,780],"class_list":{"0":"post-685","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-danish-drugmaker","9":"tag-fda-actions","10":"tag-hims-and-hers-health","11":"tag-illegal-drug-copies","12":"tag-novo-nordisk","13":"tag-price-pressure","14":"tag-stock-market-reaction","15":"tag-wegovy-pill","16":"tag-weight-loss-medications"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=685"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/685\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/686"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}